Conference Correspondent
Beth Faiman discusses the difficulty of keeping abreast of all the new multiple myeloma treatments and how she personally stays up to date on all of the information. Read Bio ›
Leslie Lauersdorf discusses the need to balance optimism and realism in caring for patients with relapsed/refractory multiple myeloma. Read Bio ›
Leslie Lauersdorf addresses the challenges associated with staying abreast of the side effects, management, and sequencing for new multiple myeloma treatments. Read Bio ›
As patients with multiple myeloma are now living longer, survivorship care is becoming more crucial. Read Bio ›
Beth Faiman identifies how the Janssen CarePath program can financially help anyone who is diagnosed with multiple myeloma and requires daratumumab. Read Bio ›
Beth Faiman expresses her main concerns regarding new treatments being studied to treat multiple myeloma. Read Bio ›
Beth Faiman discusses why it's important to communicate with and educate patients so that they can better manage their symptoms before they become more severe. Read Bio ›
Beth Faiman explains how she identfies side effects that her patients are experiencing in order to open the lines of communication to better address other issues the patient may not be aware of. Read Bio ›
Patients with newly diagnosed multiple myeloma have different needs than pateints relapsed/refractory disease, and Beth Faiman addresses what some of these needs are. Read Bio ›
Beth Faiman gets questions from her patients about daratumumab on an almost daily basis. Find out what their most asked questions are. Read Bio ›